1. Academic Validation
  2. Selective TASK-1 Inhibitor with a Defined Structure-Activity Relationship Reduces Cancer Cell Proliferation and Viability

Selective TASK-1 Inhibitor with a Defined Structure-Activity Relationship Reduces Cancer Cell Proliferation and Viability

  • J Med Chem. 2022 Nov 24;65(22):15014-15027. doi: 10.1021/acs.jmedchem.1c00378.
Bárbara Arévalo 1 Mauricio Bedoya 2 3 Aytug K Kiper 4 Fernando Vergara 5 David Ramírez 6 Yuliet Mazola 5 Daniel Bustos 2 7 Rafael Zúñiga 8 9 Rocio Cikutovic 8 Angel Cayo 8 Susanne Rinné 4 M Teresa Ramirez-Apan 10 Francisco V Sepúlveda 11 12 Oscar Cerda 13 14 Eduardo López-Collazo 15 Niels Decher 4 16 Leandro Zúñiga 8 Margarita Gutierrez 17 Wendy González 5 18
Affiliations

Affiliations

  • 1 Centro de Estudios en Alimentos Procesados-CEAP, Conicyt, Programa Regional R19A10001, Gore Maule, 3460000 Talca, Chile.
  • 2 Centro de Investigación de Estudios Avanzados del Maule (CIEAM), Vicerrectoría de Investigación y Postgrado, Universidad Católica del Maule, 3460000 Talca, Chile.
  • 3 Laboratorio de Bioinformática y Química Computacional, Departamento de Medicina Traslacional, Facultad de Medicina, Universidad Católica del Maule, 3480094 Talca, Chile.
  • 4 Institute for Physiology and Pathophysiology, Vegetative Physiology, Philipps-University of Marburg, Deutschhausstraße 1-2, 35037 Marburg, Germany.
  • 5 Centro de Bioinformática, Simulación y Modelado (CBSM), Facultad de Ingeniería, Universidad de Talca, 1 Poniente No. 1141, 3460000 Talca, Chile.
  • 6 Departamento de Farmacología, Facultad de Ciencias Biológicas, Universidad de Concepción, 4030000 Concepción, Chile.
  • 7 Laboratorio de Bioinformática y Química Computacional (LBQC), Escuela de Química y Farmacia, Facultad de Medicina, Universidad Católica del Maule, 3460000 Talca, Chile.
  • 8 Centro de Nanomedicina, Diagnóstico y Desarrollo de Fármacos (ND3), Laboratorio de Fisiología Molecular, Escuela de Medicina, Universidad de Talca, Casilla, 3460000 Talca, Chile.
  • 9 Instituto de Investigación Interdisciplinaria, Vicerrectoría Académica, Universidad de Talca, 3460000 Talca, Chile.
  • 10 Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, 04510, Coyoacán, 04510 México, DF, México.
  • 11 Centro de Estudios Científicos (CECs), 5110466 Valdivia, Chile.
  • 12 Facultad de Medicina y Ciencia, Universidad San Sebastián, 5110466 Valdivia, Chile.
  • 13 Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, 8380453 Santiago, Chile.
  • 14 Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Facultad de Medicina, Universidad de Chile, 8380453 Santiago, Chile.
  • 15 The Innate Immune Response Group and Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, 8046 Madrid, Spain.
  • 16 Marburg Center for Mind, Brain and Behavior-MCMBB, Philipps-University Marburg, 35037 Marburg, Germany.
  • 17 Laboratorio de Síntesis y Actividad Biológica, Instituto de Química de Recursos Naturales, Universidad de Talca, 1 poniente No. 1141, 3460000 Talca, Chile.
  • 18 Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Universidad de Talca, 1 Poniente No. 1141, 3460000 Talca, Chile.
Abstract

Chemical structures of selective blockers of TASK channels contain aromatic groups and amide bonds. Using this rationale, we designed and synthesized a series of compounds based on 3-benzamidobenzoic acid. These compounds block TASK-1 channels by binding to the central cavity. The most active compound is 3-benzoylamino-N-(2-ethyl-phenyl)-benzamide or F3, blocking TASK-1 with an IC50 of 148 nM, showing a reduced inhibition of TASK-3 channels and not a significant effect on different K+ channels. We identified putative F3-binding sites in the TASK-1 channel by molecular modeling studies. Mutation of seven residues to A (I118A, L122A, F125A, Q126A, L232A, I235A, and L239A) markedly decreased the F3-induced inhibition of TASK-1 channels, consistent with the molecular modeling predictions. F3 blocks cell proliferation and viability in the MCF-7 Cancer cell line but not in TASK-1 knockdown MCF-7 cells, indicating that it is acting in TASK-1 channels. These results indicated that TASK-1 is necessary to drive proliferation in the MCF-7 Cancer cell line.

Figures
Products